Research programme: vitamin D signal amplifiers - OPKO Health

Drug Profile

Research programme: vitamin D signal amplifiers - OPKO Health

Alternative Names: CTA002; CTA012; CYP24 inhibitors - Cytochroma; QW-1624F2-2

Latest Information Update: 23 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University
  • Developer Cytochroma
  • Class Vitamin D analogues
  • Mechanism of Action CYP24 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Osteoporosis; Psoriasis

Most Recent Events

  • 23 Apr 2014 Discontinued - Preclinical for Cancer in Canada (unspecified route)
  • 23 Apr 2014 Discontinued - Preclinical for Psoriasis in Canada (Topical)
  • 04 Mar 2013 OPKO Health acquires Cytochroma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top